Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are the standard of care for non‐small‐cell lung cancer (NSCLC) patients harboring EGFR mutations. However, almost all patients develop resistance after approximately 1 y of treatment, with >50% of cases due to the T790M se...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Hirashima, Tomonori, Satouchi, Miyako, Hida, Toyoaki, Nishio, Makoto, Kato, Terufumi, Sakai, Hiroshi, Imamura, Fumio, Kiura, Katsuyuki, Okamoto, Isamu, Kasahara, Kazuo, Uchida, Hirohiko, Vowler, Sarah L., Mitsudomi, Tetsuya
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726692/
https://ncbi.nlm.nih.gov/pubmed/31265163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14120
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia